Navigation Links
Sigma-Aldrich(R) Licenses RAFT Polymerization Technology From CSIRO(R)

ST. LOUIS, March 11 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) announced today that it has entered into a worldwide licensing agreement with Australia's Commonwealth Scientific and Industrial Research Organization (CSIRO) to manufacture and sell Reversible Addition-Fragmentation chain Transfer (RAFT) agents – organic molecules that can be added to polymerization reactions to precisely control molecular weights and structures of polymers.  Under the terms of the agreement, Sigma-Aldrich has the rights to manufacture and sell the RAFT agents worldwide for all research and development applications.  The RAFT agents are the latest addition to Sigma-Aldrich's growing line of polymer science products sold through its Aldrich® Materials Science Initiative.

"Commercial availability of RAFT agents is a critical requirement toward making RAFT polymerization accessible to the wider community of materials researchers," said Dr. Ilya Koltover, market segment manager for Aldrich Materials Science.  "We have successfully scaled up synthesis of RAFT agents and are pleased to offer a selection that is expected to enable researchers to explore a variety of experimental conditions without having to go through the trouble of making the RAFT agents in their own labs.  This effort is another example of the core value of Aldrich Materials Science - we focus on supplying materials so that our customers can focus on results."

RAFT technology is a living radical polymerization process and a powerful method for the synthesis of tailor-made polymers with predetermined molecular weights and highly complex architectures.  Such designer polymers can be used to prepare materials with unique properties controlled by their nanometer scale molecular architecture in industries such as biomedical, specialty chemical and personal care.  The RAFT method is applicable to a wide range of monomers and experimental conditions and its utility is reflected in more than 200 patents related to RAFT technology.  Sigma-Aldrich will manufacture and distribute the critical components of RAFT polymerization, RAFT agents, to enable companies and research organizations to undertake further research into this groundbreaking technology.

"The RAFT technology is creating global impact and has been licensed by a range of Australian and multinational companies," added Kate Dawson, CSIRO's business development manager, RAFT.  "Making RAFT agents available from Sigma-Aldrich is a big step toward enabling researchers to achieve the major improvements that RAFT can bring in areas such as coatings, biomaterials, polymer synthesis and personal care."

Sigma-Aldrich currently offers seven RAFT agents that can be supplied in quantities from standard 1g and 5g packs to several hundred grams and expects to make additional RAFT agents available later in 2010.  The new RAFT products expand the Aldrich Materials Science line of tools for controlled polymerization.  To learn more about polymer and polymerization products available from Aldrich Materials Science, please visit

Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "critical requirement," "expected to enable researchers to explore," "groundbreaking technology," "creating global impact," or similar expressions, or by express or implied discussions regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that RAFT products will continue to meet the demands of the marketplace. Nor can there be any guarantee that any of these products will achieve any particular levels of revenue in the future. In particular, management's expectations regarding these products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma-Aldrich:  Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. Sigma-Aldrich has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,700 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning website at

About CSIRO:  CSIRO Australia is one of the largest and most diverse scientific organisations in the world.  CSIRO carries out scientific research in areas including energy, the environment, information technology, health, mining, manufacturing, agriculture, and natural resources. More information on RAFT is available at  

Sigma-Aldrich® is a registered trademark of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co.

CSIRO® is a registered trademark of Commonwealth Scientific and Industrial Research Organization Corporation Australia.

SOURCE Sigma-Aldrich

Back to top



SOURCE Sigma-Aldrich
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market
2. Sigma-Aldrich(R) Receives Award From Michael J. Fox Foundation to Develop Parkinsons Disease Research Models
3. Omnyx Licenses Olympus Digital Pathology Patents
4. CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda
5. PSKW & Associates LLC Acquires Triax Media, Licenses Triax to Subsidiary, Centricity Group
6. TenX Biopharma Licenses Zanolimumab From Genmab
7. Omnicare Clinical Research Licenses LiquentConnect to Create Added Value for Clients
8. Raytheon BBN Technologies Licenses Stereo Digital Mammography Technology to FUJIFILM Corporation
9. SCOLR Pharma, Inc. Licenses Dietary Supplements
10. StemCyte Licenses Promising IP for Stem Cell Therapy to Treat Stroke
11. The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... Implant, the industry,s first MRI guided user interface and ... of patients with MR Conditional implants, such as knee ... 2015 Radiological Society of North America Annual Meeting ... and supports diagnostic confidence of this growing patient population. ...
(Date:11/30/2015)... BOCA RATON, Fla. , Nov. 30, ... of Public Research (the Institute) announced today that ... , a medical device start-up company with technology developed ... creation based on publicly-funded research, and bridges early funding ... -based universities and research institutions. ...
(Date:11/30/2015)... Nov. 30, 2015 Baxalta Incorporated ... leader dedicated to delivering transformative therapies to ... conditions, today announced the launch and first ... an extended circulating half-life recombinant factor VIII ... full-length ADVATE [Antihemophilic Factor (Recombinant)]. The treatment ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... Centers’ National Poison Data System (NPDS) reveals that in 2014, someone called a ... cases, over two million of which were human exposure cases. , The American ...
(Date:11/30/2015)... ... November 30, 2015 , ... Brenntag Specialties, Inc. ... partner for the Nutraceutical Specialties products into oral solid dosage in the over ... , “We are pleased to announce our expanded distribution agreement with ASI.” said ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announced at the Radiology Society of North America (RSNA) annual meeting, being held ... 60% growth from 2014. Throughout 2015, the company has completed installations for ...
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb – Kreithen Plastic ... surgery practices in Florida, is proud to announce that Dr. Joshua Kreithen, one ... Ethicon Inc., a Johnson & Johnson Company. , Ethicon is a global medical ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... strategic alliance around Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue repair ... polymers, TIGR® Matrix is a long-term resorbable surgical mesh intended to support and ...
Breaking Medicine News(10 mins):